Dynavax Technologies (NASDAQ:DVAX) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Dynavax Technologies Co. (NASDAQ:DVAX) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $11.62 and traded as high as $12.87. Dynavax Technologies shares last traded at $12.62, with a volume of 5,449,688 shares.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Price Performance

The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of 97.08 and a beta of 1.34. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company’s 50 day moving average is $12.72 and its 200 day moving average is $11.62.

Institutional Trading of Dynavax Technologies

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. Rhumbline Advisers lifted its stake in Dynavax Technologies by 1.8% in the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock valued at $3,490,000 after buying an additional 5,379 shares during the last quarter. Choreo LLC acquired a new stake in Dynavax Technologies during the 2nd quarter worth $363,000. State of New Jersey Common Pension Fund D purchased a new position in Dynavax Technologies during the 2nd quarter worth $1,811,000. WINTON GROUP Ltd increased its stake in Dynavax Technologies by 9.3% in the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 7,025 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after buying an additional 53,600 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.